Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas

Abstract

Purpose: Current studies and guidelines suggest that the biobehavior of IDH-wild type (IDH-wt) lower-grade glioma (LGG, WHO II-III) is similar to IDH-wt glioblastoma (GBM). However, differences in their clinical and molecular characteristics have not been reported. This study aimed to analyze the clinical and genetic information of gliomas with IDH-wt. Methods: Four hundred patients with IDH-wt were enrolled in the study (LGG = 176, GBM = 224), and their clinical and genetic information was collected from the Chinese Glioma Genome Atlas (CGGA). We conducted an analysis of this information between the two groups of patients and drew conclusions thereof. Results: The median age of the LGG patients was 42 (40–47) years, while that of the GBM patients was 51 (47–53) years (P < 0.05). GBM patients were more likely to undergo total resection (P < 0.05) and had fewer epileptic seizure symptoms (P < 0.01). The median overall survival (OS) was 51.87 months for the LGG patients and only 14.5 months for the GBM patients (P < 0.01). The median progression-free survival (PFS) was 37.6 months for the LGG patients and only 9.3 months for the GBM patients (P < 0.01). LGG patients were more prone to PETN mutations (P < 0.05). Transcriptome analysis showed that the differentially expressed genes in LGG patients were mainly enriched in metabolic pathways and pathways in cancer and in the function of signal transduction and positive regulation of GTPase activity, while in GBM patients, they were mainly enriched in the PI3K-Akt signaling pathway and in the functions of apoptotic process and oxidation-reduction process. Conclusions: Our data indicate that these two groups of patients should be re-evaluated and treated differently, despite both having IDH wild type.

Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations

“…In contrast, for East Asians, the MAD was 59 ( n = 1010) in Hong Kong, China 39 . The MAD was 51 and approximately 49 in 2 hospital-based Chinese cohorts ( Figure 2C ) 49 , 50 . In 4 Korean studies, the MAD ranged from 55.5 to 61 ( Figure 2C ) 18 , 31 , 41 , 42 , 49 .…”

“…The MAD was 51 and approximately 49 in 2 hospital-based Chinese cohorts ( Figure 2C ) 49 , 50 . In 4 Korean studies, the MAD ranged from 55.5 to 61 ( Figure 2C ) 18 , 31 , 41 , 42 , 49 . In particular, the MAD was 60 in the largest Korean cohort ( n = 5,796, 2007–2016), thus suggesting a MAD of 59–60 for East Asians 18 .…”

“…Studies are increasingly investigating the genomic landscape of glioma by including more East Asian populations to fill gaps in the genetic diversity of data 49,[78][79][80] . Notably, the Chinese Glioma Genome Atlas has collected, archived, and shared large-scale glioma omics data from the Chinese population, thus aiding in the ease and integration of studies of East Asian glioma 81 .…”